Low-dose Cytarabine plus Aclarubicin for Patients with Previously Untreated Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Ineligible for Standard-dose Cytarabine plus Anthracycline

In order to assess the role of the combination of low-dose cytarabine (Ara-C) plus aclarubicin (CA) in remission induction for patients with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), we retrospectively analyzed the efficacy and safety of CA. Data of twenty p...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2012-04, Vol.32 (4), p.1347-1353
Main Authors: FUKUSHIMA, Toshihiro, KAWABATA, Hiroshi, TANAKA, Masao, KAWANAMI, Takafumi, MASAKI, Yasufumi, OKAZAKI, Toshiro, UMEHARA, Hisanori, SAWAKI, Toshioki, SATOH, Tomomi, NAKAMURA, Takuji, IWAO, Haruka, NAKAJIMA, Akio, SAKAI, Tomoyuki, MIKI, Miyuki, FUJITA, Yoshimasa
Format: Article
Language:English
Subjects:
Aclarubicin - administration & dosage
Acute myeloid leukemia
Aged
Aged, 80 and over
Anthracycline
Anthracyclines - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Chemotherapy
cytarabine
Cytarabine - administration & dosage
Data processing
Dose-Response Relationship, Drug
Female
Granulocyte colony-stimulating factor
Hematologic and hematopoietic diseases
Humans
Infection
Injuries
Leukemia, Myeloid, Acute - drug therapy
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Leukocytosis
Lung
Male
Medical sciences
Middle Aged
Myelodysplastic syndrome
Myelodysplastic Syndromes - drug therapy
Remission
Risk groups
stem cell transplantation
Survival
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In order to assess the role of the combination of low-dose cytarabine (Ara-C) plus aclarubicin (CA) in remission induction for patients with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), we retrospectively analyzed the efficacy and safety of CA. Data of twenty patients with untreated AML or high-risk MDS who were ineligible for standard-dose Ara-C plus anthracycline and received CA as remission-induction therapy were analyzed. CA consisted of low-dose Ara-C (10 mg/m(2), subcutaneous injection every 12 hours, for 14 days) and aclarubicin (14 mg/m(2) for patients
ISSN:0250-7005
1791-7530